SCHEMBL5541784

SCHEMBL5541784

[CH2]N1CCC(Oc2cc(C(F)(F)F)cc(C(F)(F)F)c2)CC1

nearest known ligand 0.42

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
TP53 P04637 1/20 0.42
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
SLC6A2 P23975 2/20 0.41
SLC6A4 P31645 2/20 0.41
SLC6A3 Q01959 1/20 0.39
TEAD1 P28347 1/20 0.38
EPHX2 P34913 2/20 0.37
MET P08581 1/20 0.36
MMP12 P39900 1/20 0.36
MMP13 P45452 1/20 0.36
LIPG Q9Y5X9 3/20 0.35
LIPC P11150 1/20 0.35
FPR2 P25090 1/20 0.35
PROKR1 Q8TCW9 1/20 0.35
LIPE Q05469 1/20 0.35
ADRB2 P07550 1/20 0.34
CSF1R P07333 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5544454 0.84 TP53 (0.59) TP53MEN1KMT2ASLC6A2SLC6A4
SCHEMBL5536138 0.83 TEAD1 (0.53) TP53TEAD1EPHX2MMP12MMP13
SCHEMBL5541792 0.83 MET (0.48) TP53MEN1KMT2ASLC6A2SLC6A4
SCHEMBL15611338 0.77 SLC6A2 (0.43) TP53MEN1KMT2ASLC6A2SLC6A4
SCHEMBL14413039 0.77 EPHX2 (0.46) TP53MEN1KMT2ATEAD1EPHX2
SCHEMBL2203963 0.75 MET (0.45) TP53MEN1KMT2ASLC6A2SLC6A4
SCHEMBL12426535 0.75 MEN1 (0.46) TP53MEN1KMT2ASLC6A2SLC6A4
SCHEMBL13279384 0.75 KDM4E (0.46) TP53MEN1KMT2ASLC6A2SLC6A4
Hydrochloric Acid SCHEMBL4109112 0.75 HTR2C (0.49) SLC6A2SLC6A4SLC6A3
SCHEMBL25594627 0.74 BRAF (0.41) MEN1KMT2AMETLIPGCSF1R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 TP53 4494/4885MEN1 3295/4885KMT2A 4267/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.